Pharmaceutical and medical product portfolios become complex for reasons that are often more legitimate than in many other industries. A single molecule or device may exist in multiple strengths, dosage forms, pack sizes, presentations, geographies, and regulatory versions. Hospitals, pharmacies, providers, payers, and patients may each have different requirements. Some variety is unavoidable because it protects safety, access, and adherence. Some of it is historical clutter that adds cost, fragments demand, and increases regulatory and supply-chain burden without enough value in return.
That is what makes SKU rationalization in this sector distinctive. The goal is not simply to remove low-volume items. It is to simplify the portfolio while preserving patient care, provider confidence, and compliance. This chapter explores the main sources of complexity in pharmaceutical and medical product portfolios, the special role of patients, providers, and regulators in decision making, the need to protect continuity of supply while rationalizing, and the practical priorities that usually create the most value when simplification begins.
30.1 Complexity From Dosages, Formats, Pack Sizes, and Regulations
In pharmaceuticals and medical products, complexity often starts with legitimate clinical or usage differences. A product may need several strengths, routes of administration, container types, or pack sizes to serve different patient populations and care settings. Over time, however, those distinctions can multiply beyond what is clinically necessary or economically healthy. The result is a portfolio that is difficult to manufacture, register, forecast, distribute, and support.
Dosage complexity: the expansion of strengths, concentrations, and administration patterns beyond what the market or clinical need clearly requires. In generics and branded pharmaceuticals alike, a single therapy may be marketed in multiple strengths to support titration, age groups, or prescribing habits. Some of these are indispensable. Others persist because of historical preference, acquired portfolios, or incomplete harmonization across regions. If several strengths have weak volume, limited differentiation in use, and overlapping prescribing logic, they may be candidates for rationalization, provided patient and provider impact is handled carefully.
Format complexity: the multiplication of tablets, capsules, liquids, sachets, topical forms, injectables, prefilled devices, or kit presentations. In OTC and medical supplies, the same issue appears in sprays, creams, wipes, pouches, dressings, and disposable formats. Format diversity can increase convenience, compliance, or ease of administration, but it also creates separate packaging components, production steps, stability profiles, quality documentation, and training requirements. A format that appears commercially attractive may still be operationally expensive if demand is low and the presentation has unique manufacturing or handling needs.
Pack-size complexity: this is especially common in OTC medicines, medical consumables, and hospital products. Companies create multiple counts and configurations to serve retail, institutional, mail-order, and reimbursement-driven channels. Some packs support real use cases such as starter supply, chronic therapy, procedure packs, or unit-dose distribution. Others differ only slightly and divide demand unnecessarily. In regulated industries, even small pack differences can create distinct artwork, compliance review, serialization, and shelf-life management burdens.
Regulation adds a further layer. Different countries, reimbursement systems, languages, and labeling requirements can force separate SKUs even when the underlying product is similar. Some regional variation is unavoidable. Yet many organizations accumulate extra complexity because they do not periodically challenge whether all local presentations, packs, and legacy codes are still needed. Rationalization therefore begins by separating what is clinically or legally required from what has simply persisted through organizational inertia.
30.2 Managing Patient, Provider, and Regulatory Considerations
Pharmaceutical and medical product rationalization cannot be run like a standard consumer portfolio project because the end user is not choosing only on preference. Patients, prescribers, pharmacists, procurement teams, hospital committees, and regulators all influence whether a change is acceptable. That means commercial and operational logic must be filtered through a safety and care lens.
Patient consideration: the effect a SKU change may have on adherence, ease of use, dosing confidence, continuity of therapy, and perceived equivalence. A pack-size simplification that looks harmless operationally may create confusion for a patient accustomed to a given refill cadence. A format change may affect dexterity, swallowing, administration technique, or comfort. In medical products, device form factor, preparation steps, or sterile-field compatibility may matter more than the item’s direct economics. Rationalization teams therefore have to ask not only whether a substitute exists, but whether the substitute supports safe and practical use in the real care setting.
Provider consideration: the impact on prescribing, dispensing, administration workflow, and clinical confidence. Physicians, nurses, pharmacists, and procurement teams often rely on familiar product presentations, formulary logic, and handling patterns. If the company changes too much without clear transition support, the result may be confusion, resistance, or reluctance to substitute. Provider-facing rationalization therefore requires stronger communication, comparison materials, and in some cases formal review or approval through hospital committees or procurement channels.
Regulatory consideration: any requirement related to registration, labeling, packaging, controlled changes, submissions, market authorization, or quality compliance that constrains how and when a SKU can be changed or discontinued. This is one of the most important differences in the sector. A company may know that a low-volume presentation should leave the portfolio, yet still need to manage notice periods, regulatory filings, stability implications, or country-specific obligations before acting. Likewise, a substitute may be commercially obvious but not interchangeable from a labeling or approval perspective.
The practical implication is that pharmaceutical and medical product rationalization must involve medical, regulatory, quality, and pharmacovigilance or clinical stakeholders early. They should help classify which SKUs are clinically distinct, which are substitutable with proper communication, and which changes require submissions, external approvals, or formal risk assessment. The stronger this cross-functional work is, the more confidently the company can simplify without creating patient or provider disruption.
30.3 Rationalizing While Protecting Continuity of Supply and Compliance
Few industries are less tolerant of supply failure than pharmaceuticals and medical products. A stockout, discontinuation, or poorly managed substitution can affect treatment, procedures, and patient safety directly. That makes continuity of supply the central discipline in implementation. A company may be economically right to simplify a portfolio and still make a serious mistake if it destabilizes supply in the process.
Continuity of supply: the ability to maintain appropriate product availability for patients, providers, hospitals, distributors, and pharmacies through the rationalization process and after the future-state portfolio is in place. In this sector, continuity is not only a commercial concern. It is often a legal, ethical, and reputational one. For some products, especially critical therapies, sterile products, or essential consumables, even short disruptions can create outsized consequences.
That is why rationalization must be sequenced carefully. A low-volume SKU may still need to remain active until alternative stock is built, customers are notified, regulatory steps are complete, and substitute pathways are operationally ready. In some cases, the best move is not abrupt discontinuation but managed migration, where existing demand is guided into a clinically and operationally acceptable alternative over time. This is particularly important in hospital and institutional channels, where formularies, purchasing contracts, and care protocols may need to be updated before the transition is complete.
Compliance protection: ensuring that portfolio simplification does not create gaps in labeling, traceability, batch documentation, market authorization, adverse-event handling, complaint management, or other regulated processes. Even straightforward SKU exits can have hidden compliance consequences if packaging components, master data, serialization settings, or post-market surveillance processes are not updated correctly. The organization should therefore treat rationalization as a controlled change process, not simply a commercial delisting exercise.
Inventory management also requires special care. Companies must decide how to deplete obsolete packs, components, and country-specific materials without creating unsafe or noncompliant situations. Some items can be run down normally. Others may require controlled destruction, relabeling, redeployment to allowed markets, or carefully managed last-buy arrangements. The more regulated and clinically sensitive the portfolio, the less acceptable it is to improvise these decisions late.
In practice, the strongest programs separate the rationalization decision from the service strategy. A SKU can exit the standard assortment while the company still provides planned support through a transition window, a validated substitute, or a more centralized supply model. That distinction often makes simplification possible in a sector where outright removal would otherwise appear too risky.
In regulated healthcare markets, good rationalization is not retreat. It preserves access more reliably by simplifying what the network, the factory, and the regulator cannot support well.
30.4 Practical Priorities for Pharmaceutical and Medical Product Portfolios
The best rationalization opportunities in this sector usually come from removing complexity that is commercially weak, operationally expensive, and clinically or regulatorily manageable. The first priority is often to clean inactive and duplicate presentations. Many portfolios contain old local codes, overlapping pack sizes, inherited country-specific variants, or redundant hospital and retail presentations that no longer serve a distinct purpose. These are usually lower-risk opportunities because the underlying therapy or device remains available while the excess coding and packaging complexity is reduced.
The second priority is to rationalize low-value pack sizes and secondary presentations. OTC medicines, generics, wound care products, diagnostics consumables, and procedure-related items often accumulate too many counts and configurations. Where adherence, reimbursement, and care setting allow, companies can usually simplify to a smaller set of clearly defined packs that better fit demand and lower packaging complexity. The key is to confirm that the remaining packs still support major channel and patient needs.
The third priority is to review weak dosage and format tails with strong medical and regulatory input. Not every low-volume strength or format should remain simply because it exists. Some have genuine clinical importance. Others survive mainly through habit and could be replaced by adjacent strengths, alternative presentations, or updated care protocols if the transition is managed responsibly. This is where structured medical review is critical, because a financially attractive exit may still be unacceptable if clinical distinctiveness is real.
The fourth priority is to redesign regional and channel variation. Global and multi-market companies often maintain too many country-specific packs, labels, or presentations that reflect historical arrangements rather than current need. Some variation will always remain because of local regulation. But many organizations can harmonize more than they think, especially in packaging components, artwork platforms, and underlying product architecture. The benefit is not only lower SKU count. It is also lower regulatory maintenance and better supply-chain flexibility.
A practical sequence usually follows a disciplined order. First, remove obsolete and inactive items. Second, simplify duplicate packs and redundant local presentations. Third, assess low-volume strengths and formats through a joint commercial, medical, quality, and regulatory review. Fourth, redesign the future-state assortment so that the remaining range is clinically coherent, easier to supply, and simpler to maintain compliantly. Companies that do this well make the portfolio safer and stronger. They are not merely reducing item count. They are concentrating capability behind the products, packs, and presentations that genuinely support patients, providers, and the economics of the business.
